RESUMEN
l-asparaginases play a crucial role in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer that mostly affects children and teenagers. However, it is common for these molecules to cause adverse reactions during treatment. These downsides ignite the search for novel asparaginases to mitigate these problems. Thus, this work aimed to produce and characterize a recombinant asparaginase from Phaseolus vulgaris (Asp-P). In this study, Asp-P was expressed in Escherichia coli with high yields and optimum activity at 40 °C, pH 9.0. The enzyme Km and Vmax values were 7.05 mM and 1027 U/mg, respectively. Asp-P is specific for l-asparagine, showing no activity against l-glutamine and other amino acids. The enzyme showed a higher cytotoxic effect against Raji than K562 cell lines, but only at high concentrations. In silico analysis indicated that Asp-P has lower immunogenicity than a commercial enzyme. Asp-P induced biofilm formation by Candida sp. due to sublethal dose, showing an underexplored potential of asparaginases. The absence of glutaminase activity, lower immunogenicity and optimal activity similar to physiological temperature conditions are characteristics that indicate Asp-P as a potential new commercial enzyme in the treatment of ALL and its underexplored application in the treatment of other diseases.
Asunto(s)
Asparaginasa , Phaseolus , Proteínas Recombinantes , Asparaginasa/química , Asparaginasa/farmacología , Asparaginasa/genética , Asparaginasa/inmunología , Phaseolus/química , Humanos , Cinética , Proteínas Recombinantes/farmacología , Antineoplásicos/farmacología , Antineoplásicos/química , Línea Celular Tumoral , Leucemia/tratamiento farmacológico , Células K562 , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Biopelículas/efectos de los fármacos , Concentración de Iones de Hidrógeno , TemperaturaRESUMEN
L-asparaginase is an essential drug used to treat acute lymphoid leukemia (ALL), a cancer of high prevalence in children. Several adverse reactions associated with L-asparaginase have been observed, mainly caused by immunogenicity and allergenicity. Some strategies have been adopted, such as searching for new microorganisms that produce the enzyme and applying protein engineering. Therefore, this work aimed to elucidate the molecular structure and predict the immunogenic profile of L-asparaginase from Penicillium cerradense, recently revealed as a new fungus of the genus Penicillium and producer of the enzyme, as a motivation to search for alternatives to bacterial L-asparaginase. In the evolutionary relationship, L-asparaginase from P. cerradense closely matches Aspergillus species. Using in silico tools, we characterized the enzyme as a protein fragment of 378 amino acids (39 kDa), including a signal peptide containing 17 amino acids, and the isoelectric point at 5.13. The oligomeric state was predicted to be a homotetramer. Also, this L-asparaginase presented a similar immunogenicity response (T- and B-cell epitopes) compared to Escherichia coli and Dickeya chrysanthemi enzymes. These results suggest a potentially useful L-asparaginase, with insights that can drive strategies to improve enzyme production.
Asunto(s)
Asparaginasa , Simulación por Computador , Penicillium , Asparaginasa/química , Asparaginasa/inmunología , Asparaginasa/metabolismo , Penicillium/inmunología , Penicillium/enzimología , Secuencia de Aminoácidos , Proteínas Fúngicas/química , Proteínas Fúngicas/inmunología , Proteínas Fúngicas/metabolismo , Epítopos de Linfocito B/inmunología , Epítopos de Linfocito B/química , Epítopos de Linfocito T/inmunología , Epítopos de Linfocito T/química , Humanos , Aspergillus/inmunología , Aspergillus/enzimología , Escherichia coli/genética , Dickeya chrysanthemi/enzimología , Dickeya chrysanthemi/inmunología , Modelos MolecularesRESUMEN
Acute lymphoblastic leukemia (ALL) is a type of cancer with a high incidence in children. The enzyme l-asparaginase (ASNase) constitutes a key element in the treatment of this disease. Four formulations of ASNase from a bacterial source are currently available. However, these formulations are characterized by their high immunogenicity, resulting in the inactivation of the drug, as well as in the occurrence of hypersensitivity reactions in a large number of patients. In this work, we performed an immunoinformatic analysis in order to clarify structural aspects of the immunogenicity of the asparaginase from Escherichia coli and Erwinia carotovora. For this purpose, we performed the prediction of immunogenic and allergenic epitopes in the structure of asparaginases by using the relative frequency of immunogenic peptides for the eight alleles most frequently distributed worldwide. This study showed that there are no significant differences in the level of immunogenicity between the two enzymes, while asparaginase from E. coli presented a higher relative frequency of allergenic epitopes. These results are consistent with previously published reports. However, from a structural point of view, to the best of our knowledge, this is the first report describing the structural determinants that contribute to the hypersensitivity response to this treatment.
Asunto(s)
Asparaginasa/inmunología , Proteínas Bacterianas/inmunología , Epítopos/inmunología , Escherichia coli/enzimología , Pectobacterium carotovorum/enzimología , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Secuencia de Aminoácidos , Asparaginasa/efectos adversos , Asparaginasa/uso terapéutico , Proteínas Bacterianas/química , Proteínas Bacterianas/uso terapéutico , Niño , Simulación por Computador , Epítopos/química , Escherichia coli/genética , Humanos , Hipersensibilidad/etiología , Hipersensibilidad/inmunología , Pectobacterium carotovorum/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Conformación Proteica , Homología de Secuencia de Aminoácido , Especificidad de la EspecieRESUMEN
The drug l-asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). The native E. colil-asparaginase used in Brazil until recently has been manufactured by Medac/Kyowa. Then a decision was taken by the Ministry of Health in 2017 to supply the National Health System with a cheaper alternative l-asparaginase manufactured by Beijing SL Pharmaceutical, called Leuginase®. As opposed to Medac, the asparaginase that has been in use in Brazil under the trade name of Aginasa®, it was not possible to find a single entry with the terms Leuginase in the Pubmed repository. The apparent lack of clinical studies and the scarcity of safety information provided to the hospitals by the drug distributor created a debate among Brazilian pediatric oncologists about issues of safety and efficacy that culminated eventually in a court decision to halt the distribution of the new drug all over the country. Boldrini Children's Center, a non-profit pediatric oncohematology hospital, has conducted its own evaluation of Leuginase®. Mass spectrometry analyses found at least 12 different contaminating host-cell proteins (HCP) in Leuginase®. The presence of two HCP (beta-lactamase and malate dehydrogenase) was confirmed by orthogonal methodologies. The relative number of HCP peptides ranged from 19 to 37% of the total peptides identified by mass spectrometry. In vivo studies in mice injected with Leuginase® revealed a 3 times lower plasma bioavailability and the development of higher antibody titres against l-asparaginase in comparison to Aginasa®-injected animals. The decision to buy a new drug based on its price alone is not safe. Developing countries are especially vulnerable to cheaper alternatives that lack solid quality assurance.
Asunto(s)
Asparaginasa/inmunología , Escherichia coli/enzimología , Malato Deshidrogenasa/metabolismo , beta-Lactamasas/metabolismo , Secuencia de Aminoácidos , Animales , Antibacterianos/farmacología , Asparaginasa/sangre , Asparaginasa/química , Disponibilidad Biológica , Niño , Humanos , Ratones Endogámicos BALB C , Isoformas de Proteínas/química , Isoformas de Proteínas/metabolismo , Proteómica , Reproducibilidad de los Resultados , beta-Lactamasas/químicaRESUMEN
Los anticuerpos han sido ampliamente utilizados como marcadores en la detección y localización de moléculas específicas. En base al método de Cevenini et al. (1991) y utilizando bajas dosis del inmunógeno L-Asparaginasa, se obtuvieron anticuerpos policlonales desde tumores ascíticos inducidos en ratón. El fluído ascítico se sometió a fraccionamiento con sulfato de amonio y a diálisis. Por Western Blot se evidenció un enriuecimiento en inmunoglobulinas y mediante Dot Blot se determinó la especificidad del anticuerpo frente al antígeno. El abundante pool de anticuerpos obtenidos tiene alta snsibilidad por el antígeno ya que no presenta relación cruzada con los epítopes probados